Alyeska Investment Group
ORIC icon

Alyeska Investment Group’s Oric Pharmaceuticals ORIC Stock Holding History

Alyeska Investment Group’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-137,489
Closed -$1.74M – 760
2026
Q1 		$1.74M Buy
+137,489
New +$1.56M ﹤0.01% 551
2021
Q4 		– Sell
-109,945
Closed -$2.3M – 696
2021
Q3 		$2.3M Sell
109,945
-175,000
-61% -$3.55M 0.03% 484
2021
Q2 		$5.04M Sell
284,945
-500
-0.2% -$11K 0.06% 341
2021
Q1 		$6.99M Buy
285,445
+36,547
+15% +$1.15M 0.09% 267
2020
Q4 		$8.43M Buy
248,898
+87,313
+54% +$2.51M 0.12% 218
2020
Q3 		$4.04M Hold
161,585
– – 0.06% 284
2020
Q2 		$5.45M Buy
+161,585
New +$5.16M 0.08% 259

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Alyeska Investment Group's ORIC Position: Q2 2026 in Review

Alyeska Investment Group sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 137,489 shares — an estimated $1.74M sold.

Alyeska Investment Group first reported a position in ORIC in Q2 2020 and held it in 7 quarters. The position peaked at $8.43M in Q4 2020. 180 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • Alyeska Investment Group reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Alyeska Investment Group sold 137,489 Oric Pharmaceuticals shares in Q2 2026, an estimated $1.74M.
  • Alyeska Investment Group first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 7 quarters.
  • Alyeska Investment Group's Oric Pharmaceuticals position peaked at $8.43M in Q4 2020.
  • 180 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.